Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
BMC Medicine|January 12, 2026
SGLT-2 Inhibitor use and liver-related and mortality outcomes in patients with type 2 diabetes and compensated cirrhosisTien-Shin Chou, Daniel Hsiang-Te Tsai, Shieh-Chieh Shao, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 20, 2026
Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indicationsWan-Ju Annabelle Lee, Daniel Hsiang-Te Tsai, Shih-Chieh Shao, et al.
Pharmacy (Basel, Switzerland)|August 28, 2024
Evaluating the Risk-Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping ReviewDaniel Hsiang-Te Tsai, Emma Harmon, Jan Goelen, et al.
BMC Infectious Diseases|June 29, 2023
Machine learning applications on neonatal sepsis treatment: a scoping reviewColleen O'Sullivan, Daniel Hsiang-Te Tsai, Ian Chang-Yen Wu, et al.
Plos Medicine|March 6, 2026
SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulationShih-Chieh Shao, Daniel Hsiang-Te Tsai, Albert Tzu-Ming Chuang, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 24, 2025
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney diseaseDaniel Hsiang-Te Tsai, Albert Tzu-Ming Chuang, Kuan-Hung Liu, et al.
Rheumatology (Oxford, England)|April 18, 2025
Effectiveness of JAK inhibitors in biologics-naïve patients with rheumatoid arthritis: a population-based studyAlbert Tzu Ming Chuang, Daniel Hsiang-Te Tsai, Meng-Yu Weng, et al.
Ophthalmology and Therapy|February 4, 2026
Trends in First-Line Glaucoma Treatment from 2013 to 2024: A Multi-institutional and Multinational Cohort StudyLan-Hsin Chuang, Daniel Hsiang-Te Tsai, Yuan-Hsi Chan, et al.
Pageof 3